6lb5: Difference between revisions
Jump to navigation
Jump to search
m Protected "6lb5" [edit=sysop:move=sysop] |
No edit summary |
||
| (3 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
==Crystal structure of dimeric RXR-LBD complexed with full agonist NEt-3IB and TIF2 co-activator== | |||
<StructureSection load='6lb5' size='340' side='right'caption='[[6lb5]], [[Resolution|resolution]] 2.40Å' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[6lb5]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6LB5 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6LB5 FirstGlance]. <br> | |||
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.4Å</td></tr> | |||
[[Category: | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=E80:6-[ethyl-[3-(2-methylpropoxy)-4-propan-2-yl-phenyl]amino]pyridine-3-carboxylic+acid'>E80</scene></td></tr> | ||
[[Category: | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6lb5 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6lb5 OCA], [https://pdbe.org/6lb5 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6lb5 RCSB], [https://www.ebi.ac.uk/pdbsum/6lb5 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6lb5 ProSAT]</span></td></tr> | ||
[[Category: Imai | </table> | ||
[[Category: | == Disease == | ||
[[Category: | [https://www.uniprot.org/uniprot/NCOA2_HUMAN NCOA2_HUMAN] Note=Chromosomal aberrations involving NCOA2 may be a cause of acute myeloid leukemias. Inversion inv(8)(p11;q13) generates the KAT6A-NCOA2 oncogene, which consists of the N-terminal part of KAT6A and the C-terminal part of NCOA2/TIF2. KAT6A-NCOA2 binds to CREBBP and disrupts its function in transcription activation. | ||
[[Category: | == Function == | ||
[https://www.uniprot.org/uniprot/NCOA2_HUMAN NCOA2_HUMAN] Transcriptional coactivator for steroid receptors and nuclear receptors. Coactivator of the steroid binding domain (AF-2) but not of the modulating N-terminal domain (AF-1). Required with NCOA1 to control energy balance between white and brown adipose tissues.<ref>PMID:9430642</ref> | |||
== References == | |||
<references/> | |||
__TOC__ | |||
</StructureSection> | |||
[[Category: Homo sapiens]] | |||
[[Category: Large Structures]] | |||
[[Category: Imai D]] | |||
[[Category: Ito N]] | |||
[[Category: Kakuta H]] | |||
[[Category: Nakano S]] | |||
[[Category: Numoto N]] | |||
Latest revision as of 07:07, 5 October 2024
Crystal structure of dimeric RXR-LBD complexed with full agonist NEt-3IB and TIF2 co-activatorCrystal structure of dimeric RXR-LBD complexed with full agonist NEt-3IB and TIF2 co-activator
Structural highlights
DiseaseNCOA2_HUMAN Note=Chromosomal aberrations involving NCOA2 may be a cause of acute myeloid leukemias. Inversion inv(8)(p11;q13) generates the KAT6A-NCOA2 oncogene, which consists of the N-terminal part of KAT6A and the C-terminal part of NCOA2/TIF2. KAT6A-NCOA2 binds to CREBBP and disrupts its function in transcription activation. FunctionNCOA2_HUMAN Transcriptional coactivator for steroid receptors and nuclear receptors. Coactivator of the steroid binding domain (AF-2) but not of the modulating N-terminal domain (AF-1). Required with NCOA1 to control energy balance between white and brown adipose tissues.[1] References
|
| ||||||||||||||||||